Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555304 | 0.83 | POLB (0.34) | POLB | |
| SCHEMBL3488891 | 0.82 | MAPT (0.35) | MAPTNLRP3PTGDR2MCOLN3KMT2A | |
| SCHEMBL3698490 | 0.73 | ALDH1A1 (0.38) | MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL3680439 | 0.72 | TDP1 (0.32) | MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL16390035 | 0.70 | POLB (0.35) | MAPTPOLBSMN1; SMN2ALDH1A1GPR55 | |
| SCHEMBL3682972 | 0.70 | CDK4 (0.30) | — | |
| SCHEMBL29814403 | 0.70 | POLB (0.35) | POLBSMN1; SMN2LMNA | |
| SCHEMBL16390545 | 0.69 | NPC1 (0.37) | MAPTPTGDR2KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL1194744 | 0.69 | CYP19A1 (0.35) | MAPTKMT2APOLBTSHRMAPK1 | |
| SCHEMBL29380873 | 0.69 | CYP19A1 (0.35) | MAPTKMT2APOLBTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623962-B2 | Olefin functionalization by metathesis reaction | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-01-07 | — | — | US | claimed |
| US-20130030126-A1 | Olefin Functionalization By Metathesis Reaction | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-01-31 | — | — | US | claimed |
| US-20120245290-A1 | Diblock Copolymers Prepared by Cross Metathesis | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-09-27 | — | — | US | claimed |
| US-8940839-B2 | Diblock copolymers prepared by cross metathesis | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8871738-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8785562-B2 | Amphiphilic block polymers prepared by alkene metathesis | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8754170-B2 | Amphiphilic block polymers prepared by alkene | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8669330-B2 | Olefin triblock polymers via ring-opening metathesis polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8623962-B2 | Olefin functionalization by metathesis reaction | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130030126-A1 | Olefin Functionalization By Metathesis Reaction | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120245290-A1 | Diblock Copolymers Prepared by Cross Metathesis | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245294-A1 | Olefin Triblock Polymers via Ring-Opening Metathesis Polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245298-A1 | Amphiphilic Block Polymers Prepared by Alkene Metathesis | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | CETP, MTTP, APOB | MAPT 2668/4885NLRP3 425/4885PTGDR2 4819/4885 |
| US-20130030126-A1 | Olefin Functionalization By Metathesis Reaction | MAX, AP1M1, AP3M1 | MAPT 1121/4885NLRP3 995/4885PTGDR2 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.